The Evenity from Amgen Inc. - osteoporosis therapy with a defined 12-month window

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-28, 01:15. Details in the imprint.

Evenity from Amgen is one of those drugs you picture in a quiet hospital room, a nurse checking the drip while an older patient flexes stiff fingers and asks when she can climb stairs again. The monoclonal antibody targets severe osteoporosis in postmenopausal women and plays in a tightly regulated 12-month window.

What Evenity is built for

Evenity is the brand name for romosozumab, a monoclonal antibody that works by inhibiting sclerostin, a protein that slows bone formation. By blocking sclerostin, the therapy increases bone formation and to a lesser extent reduces bone resorption, addressing low bone density from two directions. In practice, it is used for women after menopause with high fracture risk, often after a spine fracture or multiple fractures.

In the EU and US, Evenity is authorized specifically for postmenopausal women with osteoporosis at high risk of fracture, such as those with a history of osteoporotic fracture or multiple risk factors. The drug is given by a healthcare professional as two subcutaneous injections once a month, delivering a total dose of 210 mg romosozumab per visit. Amgen and its partner UCB emphasize that the treatment duration is capped at 12 months, after which another anti-resorptive therapy should follow.

How the monthly injections feel

On the practical side, Evenity is a clinic-based therapy, not a pill at home. Patients typically sit in an examination chair while a nurse prepares two syringes and administers them into the upper arm, thigh, or abdomen, which feels like two quick, sharp pinches rather than a long infusion. The drug comes as a prefilled syringe that must be stored refrigerated and brought to room temperature before use, a detail that hospital pharmacists watch closely.

Dr. Robert Bradway, Amgen’s long-time CEO, has repeatedly underlined that osteoporosis drugs like Evenity fit into the company’s focus on serious chronic diseases where better adherence and outcomes matter. For the rheumatologist or endocrinologist, the appeal is that the treatment delivers a clear 12-month anabolic phase, and then the patient moves to a more maintenance-style drug such as a bisphosphonate.

Clinical data and limits

Regulators anchored Evenity’s label in large phase 3 trials such as FRAME and ARCH, which showed significant reductions in vertebral fractures compared with placebo or alendronate. In the ARCH study, patients receiving Evenity followed by alendronate had lower risk of new vertebral and clinical fractures than those on alendronate alone, a result that convinced agencies but came with a cardiovascular warning.

The US Food and Drug Administration added a boxed warning on potential increased risk of heart attack, stroke, and cardiovascular death based on imbalances seen in trials. That is why prescribing information stresses that Evenity should not be started in patients who have had a heart attack or stroke in the preceding year and should be stopped if such an event occurs. For clinicians, this safety nuance turns the drug into a targeted tool, especially for women with very low bone mineral density and recent fractures but manageable cardiovascular profiles.

Pricing and market position

In the United States, Evenity launched in 2019 at a list price reported around 1,825 USD per monthly dose, making a full 12-month course sit near 22,000 USD before discounts. Payers often negotiate rebates, so the effective cost to insurers can be lower, but the therapy still occupies the high end of osteoporosis treatment costs compared with oral generics. In Europe, pricing varies by country and health system, but the drug is generally positioned as a hospital-administered specialty product rather than a simple pharmacy item.

For Amgen, Evenity complements Prolia, its denosumab brand, which focuses more strongly on anti-resorptive effects than anabolic activity. The pairing gives physicians a portfolio approach: an initial anabolic boost with Evenity for up to 12 months followed by longer-term Prolia or another anti-resorptive. According to Amgen’s own materials, the company sees this sequence as supporting bone strength and reducing fractures in a more structured way than older one-size-fits-all regimens.

Where Amgen goes from here

All told, Evenity is part of a broader strategy where Amgen leans into biologics for chronic diseases, from bone health to inflammation and oncology. The product may never match the headline sales of an oncology blockbuster, but in osteoporosis clinics it has a distinct presence: nurses know the monthly routine, and physicians appreciate the clearly defined course.

Amgen shares (ISIN US0311621009) trade on NASDAQ under the ticker AMGN, with the last available closing price reported at 358.61 USD on 2026-06-26.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.